Drug-induced lupus: Including anti-tumour necrosis factor and interferon induced
| Autor: | David A. Isenberg, M Ahijón-Lana, S Araújo-Fernández |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Drug
Anti-nuclear antibody media_common.quotation_subject Autoimmunity medicine.disease_cause Risk Assessment Rheumatology Blisibimod Risk Factors immune system diseases Anti-histone antibodies medicine Animals Humans Lupus Erythematosus Systemic skin and connective tissue diseases media_common Biological Products Lupus erythematosus Tumor Necrosis Factor-alpha business.industry Prognosis medicine.disease Immunology Tumor necrosis factor alpha Interferons business Anti-SSA/Ro autoantibodies |
| Zdroj: | Lupus. 23:545-553 |
| ISSN: | 1477-0962 0961-2033 |
| DOI: | 10.1177/0961203314523871 |
| Popis: | Drug-induced lupus erythematosus is defined as a syndrome with clinical and serological features similar to systemic lupus erythematosus that is temporally related to continuous drug exposure and which resolves after discontinuation of this drug. More than 90 drugs, including biological modulators such as tumour necrosis factor-α inhibitors and interferons, have been identified as likely ‘culprits’. While there are no standard diagnostic criteria for drug-induced lupus erythematosus, guidelines that can help to distinguish drug-induced lupus erythematosus from systemic lupus erythematosus have been proposed and several different patterns of drug-induced lupus erythematosus are emerging. Distinguishing drug-induced lupus erythematosus from systemic lupus erythematosus is important because the prognosis of drug-induced lupus erythematosus is usually good when the drug is withdrawn. This review discusses the differences between drug-induced lupus erythematosus and systemic lupus erythematosus, the mechanisms of action of drug-induced lupus erythematosus and drugs that are usually associated with drug-induced lupus erythematosus, with particular focus on the biological treatments. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|